- Home
- PMEC vs NRSN Comparison
PMEC vs NRSN Comparison
Compare PMEC & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMEC | NRSN |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | Singapore | Israel |
| Employees | N/A | 15 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 28.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | PMEC | NRSN |
|---|---|---|
| Price | $0.70 | $0.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 63.6K | ★ 171.5K |
| Earning Date | 07-24-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.63 |
| 52 Week High | $2.44 | $2.60 |
Technical Indicators
Market Signals| Indicator | PMEC | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 45.76 | 41.04 |
| Support Level | $0.60 | $0.68 |
| Resistance Level | $0.79 | $1.30 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 39.55 | 34.24 |
Price Performance
Historical ComparisonAbout PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.